KDR and neoplasm: A paradigmatic example of in vivo modelling of judicious use of anti-angiogenic treatment has been pioneered by Winkler et al. using anti-VEGFR2 targeting in glioblastoma multiforme (GBM), able to increase pericyte coverage in mature vessels [188], and further corroborated in other tumour types [153,189].